Trials / Recruiting
RecruitingNCT06190067
Azacitidine Plus PD-1 Therapy for R/R Hodgkin Lymphoma
Azacitidine Plus PD-1 Therapy for Relapsed/Refractory Hodgkin Lymphoma
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Navy General Hospital, Beijing · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this phase 2 trial is to test the safety and efficacy of azacitidine when given together with PD-1 therapy in treating patients with relapsed/refractory classic Hodgkin lymphoma.
Detailed description
The investigators will evaluate response rate, progression free survival (PFS), overall survival (OS), and toxicity of azacytidine combined with PD-1 therapy in classic relapsed/refractory Hodgkin lymphoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Azacitidine Plus PD-1 therapy | Patients were treated by Azacytidine(75 mg/m2 subcutaneous injection qd on days 1-7) plus PD-1 therapy(200mg iv qd d8) |
Timeline
- Start date
- 2023-10-30
- Primary completion
- 2026-12-01
- Completion
- 2028-12-01
- First posted
- 2024-01-05
- Last updated
- 2024-01-30
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06190067. Inclusion in this directory is not an endorsement.